Why is Immutep facing a securities class action lawsuit?

Investors allege Immutep made misleading statements about the progress and prospects of its TACTI-004 clinical trial.

What is the TACTI-004 study mentioned in the Immutep lawsuit?

TACTI-004 is a clinical trial evaluating Immutep’s cancer treatment approach and is a key part of the company’s development pipeline.

What are investors alleging about the TACTI-004 trial?

The complaint claims Immutep knew or should have known the study faced elevated risks of failing efficacy or safety endpoints.

Why are interim futility analyses important in clinical trials?

A futility analysis evaluates whether a study is unlikely to succeed, which can lead to trial changes or termination.

What are investors claiming Immutep failed to disclose?

Plaintiffs allege the company did not fully disclose internal data suggesting higher risks of trial failure.

How could failed efficacy endpoints affect Immutep’s business?

Failure to meet efficacy goals may reduce approval prospects and weaken confidence in the treatment’s commercial potential.

What does it mean that Immutep reported “strong operational progress”?

Investors claim those statements were misleading because they allegedly did not reflect growing risks tied to trial outcomes.

How can clinical trial setbacks impact Immutep’s stock price?

Negative trial developments may lower expectations for approval and future revenue, causing stock declines.

What are efficacy and safety endpoints in a clinical trial?

Endpoints are predefined measures used to determine whether a treatment is effective and safe enough for approval.

Who may qualify to participate in the Immutep class action?

Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 may be eligible if they suffered losses.

What is the deadline to seek lead plaintiff status in the Immutep lawsuit?

Investors seeking appointment as lead plaintiff must file a motion by July 6, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims against a company for misleading statements or omissions.

What does the term “class period” mean in a securities lawsuit?

The class period is the timeframe when alleged misleading statements occurred and investors may have purchased shares.

What is a lead plaintiff in a securities class action?

The lead plaintiff is the investor selected by the court to represent the interests of all shareholders in the case.

How do investors receive compensation from a securities class action settlement?

If a settlement is reached, investors submit claim forms documenting their trades to receive a portion of the settlement fund.

Immutep Limited - Faruqi & Faruqi LLP

Immutep Limited

Join Action

Case Details

Ticker IMMP

Class Period 03/24/2025 - 03/12/2026

Lead Plaintiff Deadline 07/06/2026

Days Left to Seek Plaintiff

If you are a Immutep investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Immutep between March 24, 2025 and March 12, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

particularly following positive top-line results from Immutep’s prior TACTI-002 and INSIGHT-003 studies. Further, defendants announced in a Form-K filed with the SEC in January 30, 2026, that the trial was exhibiting “strong operational progress” and the planned interim futility analysis remained “on track for the first quarter of 2026.” In truth, Immutep was aware of or was reckless, based on its access to internal clinical data, analyses, and reports concerning the TACTI-004 trial and its planned interim futility evaluation, that then-existing information materially increased the risk that the study would fail to meet its primary efficacy and/or safety endpoints.

Lead Plaintiff Deadline: July 6, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Immutep Limited

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify